Personalis, Inc. (PSNL): Price and Financial Metrics


Personalis, Inc. (PSNL)

Today's Latest Price: $26.24 USD

0.96 (3.80%)

Updated Nov 25 4:00pm

Add PSNL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

PSNL Stock Summary

  • PSNL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.51 -- higher than merely 6.3% of US-listed equities with positive expected earnings growth.
  • PSNL's went public 1.44 years ago, making it older than just 2.08% of listed US stocks we're tracking.
  • The volatility of Personalis Inc's share price is greater than that of 91.83% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Personalis Inc, a group of peers worth examining would be EPZM, JG, CERS, PACB, and FIT.
  • Visit PSNL's SEC page to see the company's official filings. To visit the company's web site, go to www.personalis.com.

PSNL Stock Price Chart Interactive Chart >

Price chart for PSNL

PSNL Price/Volume Stats

Current price $26.24 52-week high $32.80
Prev. close $25.28 52-week low $4.27
Day low $25.20 Volume 637,900
Day high $26.50 Avg. volume 488,653
50-day MA $26.00 Dividend yield N/A
200-day MA $16.51 Market Cap 1.02B

Personalis, Inc. (PSNL) Company Bio


Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.


PSNL Latest News Stream


Event/Time News Detail
Loading, please wait...

PSNL Latest Social Stream


Loading social stream, please wait...

View Full PSNL Social Stream

Latest PSNL News From Around the Web

Below are the latest news stories about Personalis Inc that investors may wish to consider to help them evaluate PSNL as an investment opportunity.

Personalis Receives Contract Extension and New Task Order From the VA’s Million Veteran Program – Total Awarded to Date Now $175M

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Receives Contract Extension and New Task Order from the VA’s Million Veteran Program – Total Awarded to Date Now $175M

Business Wire | September 17, 2020

I've Got Some PSNL Information for You, and It's Bullish

Shares of the biotech firm Personalis could soar higher in the months ahead….PSNL

The Street RealMoney | September 16, 2020

Personalis: Deep Genomics Leader At A Good Price

Investment thesis With the recent launch of Liquid Biopsy, China expansion, machine learning platform later in the year and a slight pivot to attempting to sell population sequencing to more countries, Personalis has become an even more enticing opportunity. Developments since IPO On June 7, 2019 I published an article...

Birgir Magnusson on Seeking Alpha | August 31, 2020

Personalis prices equity offering

Personalis (PSNL) has priced its public offering of 6,578,947 common stock at $19/share, for expected gross proceeds of $125M. Underwriters' over-allotment is an additional 986,842 shares of common stock from a selling stockholder.The company will not receive any proceeds from any sale of shares by the selling stockholder."PSNL is seeing...

Seeking Alpha | August 12, 2020

Personalis Announces Pricing of Public Offering of Common Stock

MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Pricing of Public Offering of Common Stock

Business Wire | August 12, 2020

Read More 'PSNL' Stories Here

PSNL Price Returns

1-mo -0.30%
3-mo 18.89%
6-mo 121.62%
1-year 195.66%
3-year N/A
5-year N/A
YTD 140.73%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7392 seconds.